12 December 2017
There is currently no measure to predict a treatability of long-acting β-2 agonist (LABA) or long-acting muscarinic antagonist (LAMA) in patients with chronic obstructive pulmonary disease (COPD). We aimed to build prediction models for the treatment response to these bronchodilators, in order to determine the most responsive medication for patients with COPD.
We performed a prospective open-label crossover study, in which each long-acting bronchodilator was given in a random order to 65 patients with stable COPD for 4 weeks, with a 4-week washout period in between. We analyzed 14 baseline clinical traits, expression profiles of 31,426 gene transcripts, and damaged-gene scores of 6,464 genes acquired from leukocytes. The gene expression profiles were measured by RNA microarray and the damaged-gene scores were obtained after DNA exome sequencing. Linear regression analyses were performed to build prediction models after using factor and correlation analyses.
Using a prediction model for a LABA, traits found associated with the treatment response were post-bronchodilator forced expiratory volume in 1 second, bronchodilator reversibility (BDR) to salbutamol, expression of three genes ( CLN8, PCSK5, and SKP2), and damage scores of four genes ( EPG5, FNBP4, SCN10A, and SPTBN5) ( R 2=0.512, p<0.001). Traits associated with the treatment response to a LAMA were COPD assessment test score, BDR, expression of four genes ( C1orf115, KIAA1618, PRKX, and RHOQ) and damage scores of three genes ( FBN3, FDFT1, and ZBED6) ( R 2=0.575, p<0.001). The prediction models consisting only of clinical traits appeared too weak to predict the treatment response, with R 2=0.231 for the LABA model and R 2=0.121 for the LAMA model.